Literature DB >> 21559314

New options in anticoagulation for the prevention of venous thromboembolism and stroke.

Lisa R Clayville, Katherine Vogel Anderson, Shannon A Miller, Erin L St Onge.   

Abstract

Entities:  

Year:  2011        PMID： 21559314      PMCID： PMC3086087     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  63 in total

Review 1.  A new era for anticoagulants.

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Eur J Intern Med       Date:  2009-06-30       Impact factor: 4.487

Review 2.  Oral factor Xa inhibitors for venous thromboembolism prevention in major orthopedic surgery: a review.

Authors:  Davide Imberti; Domenico Prisco
Journal:  Pathophysiol Haemost Thromb       Date:  2009-12-09

Review 3.  Rivaroxaban: a novel, oral, direct factor Xa inhibitor.

Authors:  Paris J Abrams; Christopher R Emerson
Journal:  Pharmacotherapy       Date:  2009-02       Impact factor: 4.705

Review 4.  Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development.

Authors:  Bengt I Eriksson; Daniel J Quinlan; Jeffrey I Weitz
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

5.  Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity.

Authors:  Jochen Graff; Nils von Hentig; Frank Misselwitz; Dagmar Kubitza; Michael Becka; Hans-Klaus Breddin; Sebastian Harder
Journal:  J Clin Pharmacol       Date:  2007-09-14       Impact factor: 3.126

Review 6.  New anticoagulants for the prevention of venous thromboembolism.

Authors:  Cecilia Becattini; Alessandra Lignani; Giancarlo Agnelli
Journal:  Drug Des Devel Ther       Date:  2010-05-25       Impact factor: 4.162

Review 7.  What is all that thrombin for?

Authors:  K G Mann; K Brummel; S Butenas
Journal:  J Thromb Haemost       Date:  2003-07       Impact factor: 5.824

8.  Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study.

Authors:  H Buller; D Deitchman; M Prins; A Segers
Journal:  J Thromb Haemost       Date:  2008-06-06       Impact factor: 5.824

9.  Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits.

Authors:  P C Wong; E J Crain; C A Watson; B Xin
Journal:  J Thromb Haemost       Date:  2009-06-03       Impact factor: 5.824

10.  Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber.

Authors:  Mohammad Urooj Zafar; David A Vorchheimer; Juan Gaztanaga; Mauricio Velez; Daniel Yadegar; Pedro R Moreno; Satoshi Kunitada; Juan Pagan; Valentin Fuster; Juan J Badimon
Journal:  Thromb Haemost       Date:  2007-10       Impact factor: 5.249
View more
  3 in total

1.  Possible failure of novel direct-acting oral anticoagulants in management of pulmonary embolism: a case report.

Authors:  James Rankin; Menachem Nagar; Jonathan Crosby; Nojan Toomari; Richard Pietras; Uri M Ben-Zur
Journal:  J Med Case Rep       Date:  2016-12-03

2.  Chemoprophylaxis in addition to mechanical prophylaxis after total knee arthroplasty surgery does not reduce the incidence of venous thromboembolism.

Authors:  Jing Loong Moses Loh; Stephrene Chan; Keng Lin Wong; Sanjay de Mel; Eng Soo Yap
Journal:  Thromb J       Date:  2019-06-20

Review 3.  Factors Affecting the Formation and Treatment of Thrombosis by Natural and Synthetic Compounds.

Authors:  Anna Lichota; Eligia M Szewczyk; Krzysztof Gwozdzinski
Journal:  Int J Mol Sci       Date:  2020-10-27       Impact factor: 5.923
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.